T. Rowe Price Associates
EVMN

T. Rowe Price Associates’s Evommune Inc EVMN Stock Holding History

T. Rowe Price Associates’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8M Buy
1,940,939
+821,918
+73% +$19.1M ﹤0.01% 1078
2026
Q1 		$25.7M Buy
1,119,021
+336,900
+43% +$7.62M ﹤0.01% 979
2025
Q4 		$13.4M Buy
+782,121
New +$14.7M ﹤0.01% 1171

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

T. Rowe Price Associates's EVMN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Evommune Inc (EVMN) stake by 73% in Q2 2026, buying an estimated $19.1M and bringing the position to 1,940,939 shares worth $25.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

T. Rowe Price Associates first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • T. Rowe Price Associates held 1,940,939 shares of Evommune Inc worth $25.8M as of Q2 2026.
  • T. Rowe Price Associates bought 821,918 Evommune Inc shares in Q2 2026, an estimated $19.1M.
  • Evommune Inc made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1078 holding.
  • T. Rowe Price Associates first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.